[Update on the treatment of endemic hemolytic uremic syndrome. Pathogenesis and treatment of the most severe systemic complication of infections by Shiga toxin-producing Escherichia coli].

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Medicina

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 21893458
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Shiga toxins — from cell biology to biomedical applications

  2010cited by this paper
• Hemolytic uremic syndrome: pathogenesis and update of interventions

  2009cited by this paper
• Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials.

  2009cited by this paper
• Shiga toxin-producing Escherichia coli O157 in beef and chicken burgers, and chicken carcasses in Buenos Aires, Argentina.

  2009cited by this paper
• Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome—a randomized prospective pilot trial

  2009cited by this paper
• Risk Factors for Sporadic Shiga Toxin–producing Escherichia coli Infections in Children, Argentina

  2008cited by this paper
• Long-term follow-up of Argentinean patients with hemolytic uremic syndrome who had not undergone dialysis

  2007cited by this paper
• A comparison of enteropathogenic and enterohaemorrhagic Escherichia coli pathogenesis.

  2006cited by this paper
• Characterization and Epidemiologic Subtyping of Shiga Toxin–Producing Escherichia coli Strains Isolated from Hemolytic Uremic Syndrome and Diarrhea Cases in Argentina

  2006cited by this paper
• [Hemolytic uremic syndrome. Clinical manifestations. Treatment].

  2006cited by this paper
• [The epidemiology of hemolytic uremic syndrome in Argentina. Diagnosis of the etiologic agent, reservoirs and routes of transmission].

  2006cited by this paper
• Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

  2005cited by this paper
• Relative Nephroprotection During Escherichia coli O157:H7 Infections: Association With Intravenous Volume Expansion

  2005cited by this paper
• Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation.

  2005cited by this paper
• Hemolytic uremic syndrome; pathogenesis, treatment, and outcome

  2005cited by this paper
• Postdiarrheal Shiga toxin-mediated hemolytic uremic syndrome similar to septic shock.

  2005cited by this paper
• Virulence genotypes and serotypes of verotoxigenic Escherichia coli isolated from cattle and foods in Argentina

  2004cited by this paper
• Shiga toxin-encoding bacteriophages--genomes in motion.

  2004cited by this paper
• Shiga toxin-producing Escherichia coli in healthy young beef steers from Argentina: prevalence and virulence properties.

  2004cited by this paper
• Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms.

  2002cited by this paper
• Human Stx2-Specific Monoclonal Antibodies Prevent Systemic Complications of Escherichia coli O157:H7 Infection

  2002cited by this paper
• Neutralization of Shiga Toxins Stx1, Stx2c, and Stx2e by Recombinant Bacteria Expressing Mimics of Globotriose and Globotetraose

  2001cited by this paper
• The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.

  2000cited by this paper
• E. coli, antibiotics, and the hemolytic-uremic syndrome.

  2000cited by this paper
• Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection.

  1999cited by this paper
• Low levels of serum erythropoietin in children with endemic hemolytic uremic syndrome

  1998cited by this paper
• Association between severity of gastrointestinal prodrome and long-term prognosis in classic hemolytic-uremic syndrome.

  1992cited by this paper
• Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools.

  1983cited by this paper
• Heparin therapy in the hemolytic-uremic syndrome.

  1973cited by this paper
• THE HEMOLYTIC-UREMIC SYNDROME.

  1964cited by this paper
• Acute renal failure in infancy and childhood. Clinical course and treatment of 41 patients.

  1962cited by this paper

• Acute Kidney Injury in Latin America.

  2025cites this paper
• Detection of plasma anti-lipopolysaccharide (LPS) antibodies against enterohemorrhagic Escherichia coli (EHEC) in asymptomatic kindergarten teachers from Buenos Aires province.

  2023cites this paper
• Prevalence of Diarrheagenic Escherichia coli (DEC) and Salmonella spp. with zoonotic potential in urban rats in Salvador, Brazil

  2020cites this paper
• The paradigm of ground meat as source of STEC in high risk area of HUS from Argentina

  2019cites this paper
• Cathelicidin- derived PR39 protects enterohemorrhagic Escherichia coli O157:H7 challenged mice by improving epithelial function and balancing the microbiota in the intestine

  2019cites this paper
• Diagnosis and Treatment of the Hemolytic Uremic Syndrome Disease Spectrum in Developing Regions

  2014cites this paper
• Plasmapheresis in the treatment of typical haemolytic-uraemic syndrome.

  2013cites this paper